Search

Your search keyword '"Cuda, Tahleesa"' showing total 16 results
Start Over Author "Cuda, Tahleesa"
16 results on '"Cuda, Tahleesa"'

4. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy

Author

Khan, Tashbib, primary, Lyons, Nicholas J., additional, Gough, Madeline, additional, Kwah, Kayden K.X., additional, Cuda, Tahleesa J., additional, Snell, Cameron E., additional, Tse, Brian W., additional, Sokolowski, Kamil A., additional, Pearce, Lesley A., additional, Adams, Timothy E., additional, Rose, Stephen E., additional, Puttick, Simon, additional, Pajic, Marina, additional, Adams, Mark N., additional, He, Yaowu, additional, Hooper, John D., additional, and Kryza, Thomas, additional

Published
2022
Full Text
View/download PDF

5. Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer

Author

Cuda, Tahleesa J., primary, He, Yaowu, additional, Kryza, Thomas, additional, Khan, Tashbib, additional, Tse, Brian W., additional, Sokolowski, Kamil A., additional, Liu, Cheng, additional, Lyons, Nicholas, additional, Gough, Madeline, additional, Snell, Cameron E., additional, Wyld, David K., additional, Rose, Stephen, additional, Riddell, Andrew D., additional, Stevenson, Andrew R. L., additional, Thomas, Paul A., additional, Clark, David A., additional, Puttick, Simon, additional, and Hooper, John D., additional

Published
2021
Full Text
View/download PDF

6. Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma

Author

Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S., Gunter, Jennifer, Sullivan, Mitchell A., Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M., Broomfield, Amy, Gough, Madeline, Wu, Andy C, McGann, Thomas, Weroha, S. John, Haluska, Paul, Forbes, Josephine, Armes, Jane E., Barry, Sinead C., Coward, Jermaine I., Jagasia, Nisha, Chetty, Naven, Snell, Cameron E., Lourie, Rohan, Perrin, Lewis C., Hooper, John, Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S., Gunter, Jennifer, Sullivan, Mitchell A., Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M., Broomfield, Amy, Gough, Madeline, Wu, Andy C, McGann, Thomas, Weroha, S. John, Haluska, Paul, Forbes, Josephine, Armes, Jane E., Barry, Sinead C., Coward, Jermaine I., Jagasia, Nisha, Chetty, Naven, Snell, Cameron E., Lourie, Rohan, Perrin, Lewis C., and Hooper, John

Abstract

High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses—of more than 10-fold lower than previously reported for other cancers—significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.

Published
2020

7. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Author

Harrington, Brittney S., He, Yaowu, Khan, Tashbib, Puttick, Simon, Conroy, Paul J., Kryza, Thomas, Cuda, Tahleesa, Sokolowski, Kamil A., Tse, Brian W.C., Robbins, Katherine K., Arachchige, Buddhika J., Stehbens, Samantha J., Pollock, Pamela M., Reed, Sarah, Weroha, S. John, Haluska, Paul, Salomon, Carlos, Lourie, Rohan, Perrin, Lewis C., Law, Ruby H.P., Whisstock, James C., Hooper, John D., Harrington, Brittney S., He, Yaowu, Khan, Tashbib, Puttick, Simon, Conroy, Paul J., Kryza, Thomas, Cuda, Tahleesa, Sokolowski, Kamil A., Tse, Brian W.C., Robbins, Katherine K., Arachchige, Buddhika J., Stehbens, Samantha J., Pollock, Pamela M., Reed, Sarah, Weroha, S. John, Haluska, Paul, Salomon, Carlos, Lourie, Rohan, Perrin, Lewis C., Law, Ruby H.P., Whisstock, James C., and Hooper, John D.

Abstract

CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival in vitro, and tumor growth and metastasis in vivo. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer.Methods: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes. In vivo, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells in vitro and in vivo.Results: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells in vitro and in vivo.Conc

Published
2020

8. PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer

Author

Cuda, Tahleesa J., primary, Riddell, Andrew D., additional, Liu, Cheng, additional, Whitehall, Vicki L., additional, Borowsky, Jennifer, additional, Wyld, David K., additional, Burge, Matthew E., additional, Ahern, Elizabeth, additional, Griffin, Alison, additional, Lyons, Nicholas J.R., additional, Rose, Stephen E., additional, Clark, David A., additional, Stevenson, Andrew R.L., additional, Hooper, John D., additional, Puttick, Simon, additional, and Thomas, Paul A., additional

Published
2020
Full Text
View/download PDF

9. Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

Author

Khan, Tashbib, primary, He, Yaowu, additional, Kryza, Thomas, additional, Harrington, Brittney S., additional, Gunter, Jennifer H., additional, Sullivan, Mitchell A., additional, Cuda, Tahleesa, additional, Rogers, Rebecca, additional, Davies, Claire M., additional, Broomfield, Amy, additional, Gough, Madeline, additional, Wu, Andy C., additional, McGann, Thomas, additional, Weroha, S. John, additional, Haluska, Paul, additional, Forbes, Josephine M., additional, Armes, Jane E., additional, Barry, Sinead C., additional, Coward, Jermaine I., additional, Jagasia, Nisha, additional, Chetty, Naven, additional, Snell, Cameron E., additional, Lourie, Rohan, additional, Perrin, Lewis C., additional, and Hooper, John D., additional

Published
2020
Full Text
View/download PDF

10. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma

Author

Kryza, Thomas, primary, Khan, Tashbib, additional, Puttick, Simon, additional, Li, Chao, additional, Sokolowski, Kamil A, additional, Tse, Brian WC, additional, Cuda, Tahleesa, additional, Lyons, Nicholas, additional, Gough, Madeline, additional, Yin, Julia, additional, Parkin, Ashleigh, additional, Deryugina, Elena I, additional, Quigley, James P., additional, Law, Ruby H. P., additional, Whisstock, James C., additional, Riddell, Andrew D., additional, Barbour, Andrew P., additional, Wyld, David K., additional, Thomas, Paul A., additional, Rose, Stephen, additional, Snell, Cameron E., additional, Pajic, Marina, additional, He, Yaowu, additional, and Hooper, John D., additional

Published
2020
Full Text
View/download PDF

11. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Author

Harrington, Brittney S., primary, He, Yaowu, additional, Khan, Tashbib, additional, Puttick, Simon, additional, Conroy, Paul J., additional, Kryza, Thomas, additional, Cuda, Tahleesa, additional, Sokolowski, Kamil A, additional, Tse, Brian WC, additional, Robbins, Katherine K., additional, Arachchige, Buddhika J., additional, Stehbens, Samantha J., additional, Pollock, Pamela M., additional, Reed, Sarah, additional, Weroha, S. John, additional, Haluska, Paul, additional, Salomon, Carlos, additional, Lourie, Rohan, additional, Perrin, Lewis C., additional, Law, Ruby H. P., additional, Whisstock, James C., additional, and Hooper, John D, additional

Published
2020
Full Text
View/download PDF

15. PET Imaging Quantifying 68 Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer.

Author

Cuda TJ, Riddell AD, Liu C, Whitehall VL, Borowsky J, Wyld DK, Burge ME, Ahern E, Griffin A, Lyons NJR, Rose SE, Clark DA, Stevenson ARL, Hooper JD, Puttick S, and Thomas PA

Subjects
Colorectal Neoplasms pathology, Colorectal Neoplasms radiotherapy, Dipeptides therapeutic use, Edetic Acid pharmacokinetics, Gallium Isotopes, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring therapeutic use, Humans, Lutetium, Neoplasm Metastasis, Prostate-Specific Antigen, Radioisotopes, Colorectal Neoplasms diagnostic imaging, Edetic Acid analogs & derivatives, Oligopeptides pharmacokinetics, Positron-Emission Tomography methods, Radiopharmaceuticals pharmacokinetics
Abstract

At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177 Lu-PSMA-617, is used to treat metastatic prostate cancer. 177 Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed 68 Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for 177 Lu-PSMA-617 PRRT., (© 2020 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2020
Full Text
View/download PDF

16. Indocyanine green fluorescence angiography (ICGFA) during laparoscopic and robotic colorectal surgery- a video vignette.

Author

Hamilton AER, Cuda TJ, Westwood DA, and Stevenson ARL

Abstract

Anastomotic leaks are a dreaded complication of all colorectal surgery with the main factors contributing to it being tension on the anastomosis, intra-abdominal or systemic sepsis, distal obstruction, inadequate blood supply and improper surgical techniques. The leak rate of left-sided high colorectal resections can have a clinically significant leak rate from as low as 1-5% in high anterior resections to 7.9% in low anastomoses. This article is protected by copyright. All rights reserved., (This article is protected by copyright. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results